10x Genomics Inc Class A

TXG

$140.84

+116.79% (1 year change)

Avg closing price

Price range

Market Cap

$22.1 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$42.9 Million

Total revenue in the last quarter.

Net Income

$-40.2 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$-1.35

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-103.64x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-39.1 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

584

The number of full time employees.

Revenue & Earnings

Balance Sheet

10x Genomics Inc Class A

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.

News

Current focus is on scaling up capabilities: 10x Genomics CEO Serge Saxonov

Current focus is on scaling up capabilities: 10x Genomics CEO Serge Saxonov

10x Genomics, Inc. (NASDAQ: TXG), a pioneer in single-cell genomics, has been eliciting significant investor interest ever since it went public more than a year ago. The biotechnology firm has […]

AlphaStreet AlphaStreet, 9 days ago
Morgan Stanley Stick to Their Buy Rating for 10x Genomics Inc

Morgan Stanley Stick to Their Buy Rating for 10x Genomics Inc

Morgan Stanley Stick to Their Buy Rating for 10x Genomics Inc

Investing.com Investing.com, 16 days ago
Torex Gold Resources beats on revenue (OTCMKTS:TORXF)

Torex Gold Resources beats on revenue (OTCMKTS:TORXF)

Torex Gold Resources (OTCPK:TORXF): Q3 Non-GAAP EPS of $0.59; GAAP EPS of $0.69. Revenue of $256.5M (+29.4% Y/Y) beats by $3.52M. Press Release

Seeking Alpha Seeking Alpha, 24 days ago